New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
16:34 EDTSPLK, NPSP, VRX, RTRX, LGF, AGN, SHPG, BLOXOn The Fly: Closing Wrap
The market began the session in quiet fashion and remained that way throughout the day. There was little for investors to get excited about, as the day’s economic data proved to be a mixed bag. The averages moved in a narrow range on very light volume while the news flow slowed to a trickle. With memorial Day kicking off the summer season and the week shortened by a day, investors appeared content to let the market drift in the last trading day of the week and the month, albeit near record levels. ECONOMIC EVENTS: In the U.S., personal income rose 0.3% in April, matching expectations, while consumer spending fell 0.1%, versus an expected increase of 0.2%. The Chicago ISM index rose 2.5 points to 65.5 in May, which was much better than expected. The final University of Michigan consumer confidence reading for May came in at 81.9, which was up just 0.1 from the prior reading and a hair below the expected 82.5 figure. COMPANY NEWS: Valeant Pharmaceuticals (VRX) raised its offer for Allergan (AGN) for the second time this week. Under the newly revised proposal, each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, plus a Contingent Value Right for DARPin of up to $25.00 per share in value. This is up from the $58.30 in cash, plus shares and the CVR, that Valeant offered just two days ago. MAJOR MOVERS: Among the notable gainers was Retrophin (RTRX), which gained $1.74, or 13.51%, to $14.62 after announcing a license agreement with Mission Pharmacal for Thiola and revising its guidance. Also higher was NPS Pharmaceuticals (NPSP), which jumped $3.68, or 13.41%, to $31.13 after FT Alphaville, citing "usually well informed sources," said Shire (SHPG) has held internal discussions about a potential cash takeover offer for its smaller pharmaceutical industry peer. Among the noteworthy losers was Infoblox (BLOX), which plunged $7.56, or 36.84%, to $12.96 after the company's outlook for the new quarter missed expectations, its CEO Robert Thomas said he will step down and the shares were downgraded by at least six Street research firms. Other decliners following their earnings reports were data analysis software provider Splunk (SPLK), which fell $8.18, or 16.35%, to $41.86, and "Hunger Games" producer Lions Gate (LGF), which dropped $3.40, or 11.51%, to $26.13. INDEXES: The Dow was up 18.43, or 0.11%, to 16,717.17, the Nasdaq was down 5.33, or 0.13%, to 4,242.62, and the S&P 500 was up 3.54, or 0.18%, to 1,923.57.
News For AGN;VRX;BLOX;LGF;NPSP;SHPG;RTRX;SPLK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 12, 2014
16:53 EDTAGNAllergan receives FDA approval for new styles of NATRELLE 410
Subscribe for More Information
10:09 EDTAGN, VRXActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTAGNActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
07:01 EDTAGNAllergan announces approval of amendments to company bylaws
Subscribe for More Information
06:22 EDTVRX, AGNZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTAGN, VRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
10:00 EDTSPLKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTVRX, AGNValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
07:22 EDTSPLKSplunk initiated with a Neutral at Macquarie
Subscribe for More Information
07:13 EDTSPLKSplunk initiated with a Neutral at Macquarie
November 10, 2014
16:39 EDTRTRXRetrophin names Stephen Aselage as CEO
Subscribe for More Information
16:08 EDTNPSPNPS Pharmaceuticals sees FY14 OpEx $185M-$195M vs. prior view of $180M-$200M
Subscribe for More Information
16:07 EDTNPSPNPS Pharmaceuticals sees FY14 revenue at low end of $100M-$110M range
Subscribe for More Information
16:06 EDTNPSPNPS Pharmaceuticals reports Q3 EPS (2c), consensus 2c
Subscribe for More Information
15:44 EDTSPLKAmazon Web Services to hold a conference
Subscribe for More Information
15:26 EDTNPSPNotable companies reporting after market close
Subscribe for More Information
10:14 EDTLGFHigh option volume stocks
High option volume stocks: UN PAGP PHH RGLS DF URA CERS DNDN LGF CALL
07:35 EDTSPLKSplunk volatility increases into Q3 and outlook
Splunk November call option implied volatility is at 92, December is at 65, January is at 57; compared to it 26-week average of 56 according to Track Data, suggesting large price movement into the expected release of Q3 on November 20.
November 9, 2014
13:26 EDTAGN, VRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use